As most manufacturers experienced firsthand, operating during a pandemic is challenging. Pfizer manufactures more than 23 billion doses of biopharmaceutical products – ranging from solid oral doses to vaccines and sterile injectables – across a network of 42 global manufacturing sites. Accomplishing this task during a pandemic intensified the […]

Click here to view original web page at www.industryweek.com